Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Karuna Therapeutics, Inc.

At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. 
 
Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions.
 
Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
 
We invite you to join us on LinkedIn and Twitter (@KarunaTx) to stay up to date on our work.

Eventide

Fidelity

Fidelity Management and Research Company

Alexandria Venture Investments

Sands Capital Ventures

Sofinnova Investments

ARCH Venture Partners

Partner Fund Management

Pivotal bioVenture Partners

PureTech Health

Wellcome Trust

Karuna Therapeutics

Today on #February11, we join others around the globe to celebrate International Day of Women and Girls in Science. We especially want to recognize the brilliant women in science on our team. Their leadership and dedication are helping us push the boundaries of innovation in neuroscience, and the best is yet to come! #EquityinScience

Bebe Moore Campbell was a fearless mental health advocate and literary trailblazer who used her words and platform to address the impacts of racism, mental health, culture, and community. This #BlackHistoryMonth, we honor and remember her legacy as well as other Black pioneers who helped shape the #MentalHealth landscape. Learn more about their contributions: https://lnkd.in/dPDdCfR

Schizophrenia is a brain disorder that distorts the way a person thinks, feels, and behaves. While current antipsychotic therapies can help treat some symptoms, such as hallucinations and delusions, they may not fully address symptoms such as memory impairment, decision-making, and the ability to enjoy life – leading to low treatment adherence. Learn more about our commitment to addressing these needs: https://lnkd.in/gmN8ykmx 

Signs and symptoms of #schizophrenia are not “one size fits all.” Schizophrenia symptoms can differ from person to person, but they generally fall into three categories. Learn more about them here: https://lnkd.in/gmN8ykmx 

Wishing you #HappyHolidays from all of us at Karuna! May you find peace and enjoy the company of your loved ones during this season. 

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue					36.96M -	10.64M 71.22%	654K 93.85%
cost of revenue							1.70M -
gross profit					36.96M -	10.64M 71.22%	-1.05M 109.84%
selling and marketing expenses
general and administrative expenses	1.19M -	2.97M 149.92%	20.87M 601.71%	28.41M 36.13%	52.62M 85.22%	76.07M 44.57%	131.33M 72.65%
selling general and administrative expenses	1.19M -	2.97M 149.92%	20.87M 601.71%	28.41M 36.13%	52.62M 85.22%	76.07M 44.57%	131.33M 72.65%
research and development expenses	3.62M -	11.54M 219.03%	24.54M 112.69%	43.41M 76.92%	128.20M 195.34%	224.25M 74.92%	364.10M 62.37%
other expenses					254K -	580K 128.35%	588K 1.38%
cost and expenses	4.81M -	14.51M 201.91%	45.41M 212.92%	71.82M 58.17%	180.82M 151.78%	300.31M 66.09%	495.43M 64.97%
operating expenses	4.81M -	14.51M 201.91%	45.41M 212.92%	71.82M 58.17%	180.82M 151.78%	300.31M 66.09%	495.43M 64.97%
interest expense	1.17M -	2.58M 120.58%	945K 63.41%			14.18M -
ebitda	-4.80M -	-14.48M 201.33%	-42.88M 196.13%	-68.51M 59.78%	-143.15M 108.95%	-289.68M 102.36%	-493.08M 70.22%
operating income	-4.81M -	-14.51M 201.91%	-45.41M 212.92%	-71.82M 58.17%	-143.85M 100.31%	-289.68M 101.37%	-494.78M 70.80%
depreciation and amortization	1K -	6K 500%	2.53M 42,033.33%	3.31M 30.74%	702K 78.76%	1.11M 58.40%	1.70M 52.97%
total other income expenses net	-55K -	-444K 707.27%	1.45M 426.13%	3.31M 128.25%	54K 98.37%	14.76M 27,229.63%	588K 96.02%
income before tax	-6.03M -	-17.51M 190.32%	-43.96M 151.01%	-68.51M 55.86%	-143.80M 109.89%	-274.92M 91.18%	-433.01M 57.51%
income tax expense	1.17M -	-419K 135.78%	887K 311.69%	43K 95.15%	6K 86.05%	1.42M 23,533.33%	670K 52.75%
net income	-6.03M -	-17.51M 190.32%	-44.84M 156.08%	-68.55M 52.87%	-143.81M 109.77%	-276.34M 92.16%	-433.68M 56.94%
weighted average shs out	7.42M -	10.87M 46.41%	11.96M 10.06%	26.45M 121.15%	29.14M 10.18%	31.63M 8.55%	36.96M 16.85%
weighted average shs out dil	7.42M -	10.87M 46.41%	11.96M 10.06%	26.45M 121.15%	29.14M 10.18%	31.63M 8.55%	36.96M 16.85%
eps	-0.81 -	-1.61 98.77%	-3.75 132.92%	-2.59 30.93%	-4.94 90.73%	-8.74 76.92%	-11.73 34.21%
epsdiluted	-0.81 -	-1.61 98.77%	-3.75 132.92%	-2.59 30.93%	-4.94 90.73%	-8.74 76.92%	-11.73 34.21%

COM:KARUNATX

Karuna Therapeutics, Inc.

Last Close

329.74

15/03 20:00

Market Cap

12.60B

Beta: -

Volume Today

1.28M

Avg: -

Preview